Home›Trial›NCT07001319
🔬NCT07001319Phase 1RECRUITING

Study of GS-3242 in Participants With HIV-1; Substudy-05

Study Summary

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Conditions
HIV-1-infection
Interventions / Drugs
GS-3242BVYStandard of Care
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F24/100
Study Details
Enrollment30 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.112974+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.